Literature DB >> 29314085

New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and time from diagnosis to cardiac resynchronization therapy: The NEOLITH II study.

Norman C Wang1, Jack Z Li1, Evan C Adelstein1, Andrew D Althouse1, Michael S Sharbaugh1, Sandeep K Jain1, G Stuart Mendenhall1, Alaa A Shalaby1, Andrew H Voigt1, Samir Saba1.   

Abstract

BACKGROUND: The optimal timing for cardiac resynchronization therapy (CRT) after diagnosis of new-onset left bundle branch block (LBBB)-associated idiopathic nonischemic cardiomyopathy (NICM) and treatment with guideline-directed medical therapy (GDMT) is unknown. The purpose of this study was to describe relationships between time from diagnosis to CRT and outcomes in new-onset LBBB-associated idiopathic NICM with left ventricular ejection fraction (LVEF) ≤35%.
METHODS: A retrospective cohort study examined associations between time from diagnosis to CRT (≤9 months vs >9 months) and clinical and echocardiographic outcomes.
RESULTS: In 123 subjects with LBBB-associated idiopathic NICM, time from diagnosis to CRT was ≤9 months in 60 (49%) subjects and 9 months in 63 (51%) subjects. Clinical outcomes were similar for those implanted ≤9 months versus >9 months for adverse clinical events (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.41-1.78; P = 0.67) and all-cause mortality (HR, 0.57; 95% CI, 0.19-1.70; P = 0.31). Multivariable analyses demonstrated similar results. In 105 subjects with post-CRT echocardiograms, LVEF improvement to >35% was more likely in those implanted ≤9 months when compared to >9 months (odds ratio [OR], 3.53; 95% CI, 1.32-9.46; P = 0.01). This association persisted in the final multivariable model adjusted for age at diagnosis, sex, QRS duration, post-GDMT LVEF, and time from CRT to post-CRT echocardiogram (OR, 5.10; 95% CI, 1.71-15.22; P = 0.004).
CONCLUSION: In LBBB-associated idiopathic NICM, earlier CRT implantation was associated with more favorable cardiac remodeling. Delaying CRT may miss a critical period to halt and reverse progressive myocardial damage.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac resynchronization therapy; left bundle branch block; left ventricular ejection fraction; nonischemic cardiomyopathy; pathophysiology

Mesh:

Year:  2018        PMID: 29314085     DOI: 10.1111/pace.13264

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

1.  Myocardial recovery after cardiac resynchronization therapy in left bundle branch block-associated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy.

Authors:  Norman C Wang; Aliza Hussain; Evan C Adelstein; Andrew D Althouse; Michael S Sharbaugh; Sandeep K Jain; Alaa A Shalaby; Andrew H Voigt; Samir Saba
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-09-28       Impact factor: 1.468

2.  Sex-specific clinical outcomes after cardiac resynchronization therapy in left bundle branch block-associated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy.

Authors:  Norman C Wang; Ure Mezu-Chukwu; Evan C Adelstein; Andrew D Althouse; Michael S Sharbaugh; Sandeep K Jain; Alaa A Shalaby; Andrew H Voigt; Samir Saba
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-03-27       Impact factor: 1.468

Review 3.  Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling.

Authors:  Edward Sze; James P Daubert
Journal:  J Interv Card Electrophysiol       Date:  2018-07-17       Impact factor: 1.900

4.  Prevalence, clinical and instrumental features of left bundle branch block-induced cardiomyopathy: the CLIMB registry.

Authors:  Giuseppe D Sanna; Annamaria De Bellis; Massimo Zecchin; Eleonora Beccu; Patrizia Carta; Eleonora Moccia; Mario E Canonico; Guido Parodi; Gianfranco Sinagra; Marco Merlo
Journal:  ESC Heart Fail       Date:  2021-09-12

5.  Predicting the Development of Reduced Left Ventricular Ejection Fraction in Patients With Left Bundle Branch Block.

Authors:  Brett D Atwater; Kasper Emerek; Zainab Samad; Edward Sze; Eric Black-Maier; Zak Loring; Martin Ugander; Lawrence Liao; Joseph Kisslo; Peter Søgaard; Daniel J Friedman
Journal:  Am J Cardiol       Date:  2020-09-28       Impact factor: 2.778

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.